Bioactive Compound Applications in Cancer and Inflammation

Bioactive compounds derived from natural sources have emerged as potent agents in the modulation of cancer and inflammatory processes. Phytochemicals such as polyphenols, flavonoids and coumestans exhibit a range of biological activities, including the induction of programmed cell death, attenuation of pro-inflammatory signalling and restoration of redox balance. These molecules may engage multiple molecular targets—cytokine networks, kinase cascades and transcription factors—to inhibit tumour proliferation, metastasis and inflammatory tissue damage. Advances in extraction, structural elucidation and high-throughput screening have accelerated the discovery of novel small-molecule leads. Integration of cell-based assays, animal models and computational docking has refined understanding of structure–activity relationships, guiding optimisation for improved potency and selectivity. Translational studies emphasise the global significance of bioactive agents for the development of safer, more cost-effective therapies for cancer and chronic inflammatory diseases.

Research from Nature Portfolio

One seminal study interrogated a bioactive fraction from a traditional medicinal herb, revealing selective cytotoxicity against breast cancer cells with minimal effects on non-tumorigenic counterparts. Mechanistic experiments demonstrated activation of the intrinsic apoptotic pathway via disruption of mitochondrial membrane potential, concomitant upregulation of Hsp60 and downregulation of the anti-apoptotic protein XIAP. Notably, Hsp60 was found to translocate to the endoplasmic reticulum during apoptosis, uncovering a novel subcellular role. Mass-spectrometry analysis identified luteolin as the principal active flavonoid, and in vivo administration mitigated tumour growth without inducing hepato-renal toxicity, underscoring its translational promise.

Bioactive Compound Applications in Cancer and Inflammation publication trend

The graph below shows the total number of articles in bioactive compound applications in cancer and inflammation across all publications each year (not limited to Nature Index journals).

Technical terms

Apoptosis: Programmed cell death characterised by energy-dependent biochemical events leading to cell shrinkage and DNA fragmentation.

Intrinsic apoptotic pathway: Mitochondria-mediated cascade triggering caspase activation following membrane potential disruption.

NF-κB signalling: Transcription factor pathway that regulates genes involved in inflammation, immune response and cell survival.

Phosphodiesterase-4 (PDE4): Enzyme that degrades cyclic AMP, its inhibition elevates intracellular signalling to reduce inflammation.

Hsp60: Heat-shock protein functioning as a mitochondrial chaperone; its mislocalisation can signal apoptotic pathways.

Cytokines: Small proteins such as tumour necrosis factor-α and interleukins that mediate and regulate inflammation.

Flavonoids: Polyphenolic compounds with antioxidant, anti-inflammatory and anticancer properties found in plants.

Coumestan: Class of plant-derived phenolic compounds noted for anti-inflammatory and antiproliferative activities.

MTT assay: Colourimetric method for assessing cell viability based on mitochondrial reduction of MTT reagent.

Colony-formation assay: In vitro test measuring a single cell’s ability to grow into a colony, indicative of proliferative capacity.

References

1. Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis. Scientific Reports (2015).
2. Wedelolactone inhibits LPS-induced pro-inflammation via NF-kappaB Pathway in RAW 264.7 cells. Journal of Biomedical Science (2013).
3. Antioxidant and Antiproliferative Activities of Eclipta prostrata (L.) L. Extract and Isolated Compounds. Molecules (2023).
4. In vitro anticancer activity of Eclipta alba whole plant extract on colon cancer cell HCT-116. BMC Complementary Medicine and Therapies (2020).